Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of April 2006
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
April 21, 2006
pSivida
Limited
By:/s/
Aaron
Finlay
_________________________________
Aaron
Finlay
Chief
Financial Officer and Company Secretary
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
pSivida
to present at UBS Global Specialty Pharmaceuticals
Conference
|
-2-
ASX/MEDIA
RELEASE
21
April 2006
pSivida
to present at UBS
Global Specialty Pharmaceuticals Conference
Presentation
in New York to be webcast live
Boston,
MA and Perth, Australia - Global bio-nanotech company pSivida Limited
(NASDAQ:PSDV,
ASX:PSD, Xetra:PSI)
today
announced that an audio of its corporate
presentation to be delivered by Dr Paul Ashton, Director of Strategy, will
be
webcast live by UBS from New York City on Tuesday, 25th
April
2006 at 4:00pm EDT (4:00am WST Australia on Wednesday, 26th
April
2006). The presentation may be accessed under the investor relations/ company
presentations tab at www.psivida.com.
The
UBS
Global Specialty Pharmaceuticals Conference
is
presented by UBS Investment Bank, one of the world’s leading financial
institutions and features many of the world’s leading pharmaceutical companies.
The audio webcast may be accessed at www.ibb.ubs.com.
Click
on the "Conferences" icon in the centre right of the page and follow the link
to
“webcast” next to the "Global Specialty Pharmaceuticals" Conference
heading.
pSivida
is a global bio-nanotech company committed to the development
of drug delivery products
in the
healthcare sector, initially
in
ophthalmology and oncology. pSivida
has developed the only two FDA approved sustained release back of the eye
treatments for chronic eye disease - Vitrasert®
and
RetisertTM.
Both
products are manufactured and sold by global ophthalmology company, Bausch
&
Lomb (B&L). RetisertTM
is also
promoted by Novartis Ophthalmic, a business unit of Novartis Pharmaceuticals,
in
collaboration with B&L. A next generation product, MedidurTM
in Phase
III clinical trials, is licensed to Alimera Sciences for the treatment of
Diabetic Macular Edema, a leading cause of vision loss for Americans under
the
age of 65.
pSivida
owns the rights to develop and commercialize a modified form (porosified or
nano-structured) of silicon known as BioSilicon™, which has applications in drug
delivery, wound healing, orthopedics, and tissue engineering. pSivida’s
lead BioSilicon™
product
is BrachySilTM,
a
brachytherapy product in pivotal Phase IIb clinical trials, which is being
developed for the treatment of inoperable primary liver cancer. Phase IIa
clinical trials demonstrated significant tumor regression as well as being
both
safe and well tolerated in humans. pSivida has a licensing agreement with
Beijing Med-Pharm Corporation for the clinical development, marketing and
distribution of BrachySil™ in China.
pSivida
has four evaluation agreements for the Company’s drug delivery technologies
with three of the five largest pharmaceutical companies in the world and
recently announced a further evaluation agreement with an undisclosed global
medical device company to evaluate cardiovascular
delivery of drugs using pSivida’s drug delivery technologies.
-ENDS-
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7638 9571
mark.swallow@citigatedr.co.uk
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert™ is FDA approved for the
treatment of uveitis. Vitrasert® is FDA approved for the treatment of
AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks; Vitrasert® and
Retisert™. pSivida has licensed the technologies underlying both of these
products to Bausch & Lomb. The technology underlying Medidur™, a treatment
for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
III
clinical trials.
pSivida
owns the rights to develop and commercialise a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopaedics, and tissue
engineering. pSivida’s subsidiary, AION Diagnostics Limited is developing
diagnostic products and the subsidiary pSiNutria is developing food technology
products both using BioSilicon™.
pSivida’s
intellectual property portfolio consists of 70 patent families, 74 granted
patents and over 290 patent applications.
pSivida
conducts its operations from offices and facilities near Boston in
Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
Singapore.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
The
Company's largest shareholder and a strategic partner is QinetiQ, a leading
international defence, security and technology company, formed in July 2001
from
the UK Government's Defence Evaluation & Research Agency
(DERA). QinetiQ was instrumental in discovering BioSilicon(TM)
and
pSivida enjoys a strong relationship with it having access to its cutting edge
research and development facilities. For more information visit www.QinetiQ.com
For
more
information, visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. The statements are indicated by the use of words such as
"believes", "expects", "anticipates" and similar words and phrases.
Although we believe that the expectations reflected in such forward-looking
statements are reasonable at this time, we can give no assurance that such
expectations will prove to be correct. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward-looking statements. Actual
results could differ materially from those anticipated in these forward-looking
statements due to many important factors including: the failure of the results
of the Retisert for DME trial to be a good indicator of
the
results of pSivida’s ongoing Phase III
Medidur™
for DME trial; failure of the
Medidur™
trials
in DME to show a very similar improvement in visual acuity and diabetic
retinopathy severity score as Retisert™
for
DME;
inability to recruit patients for the Phase
III
Medidur™
for DME trial; our failure to develop applications for BioSiliconTM
due to
regulatory, scientific or other issues, our inability to successfully integrate
CDS’ operations and employees; the failure of the CDS’ products to achieve
expected revenues and the combined entity’s inability to develop existing or
proposed products; the failure of the Bausch & Lomb/Novartis co-promotion
arrangement to provide faster royalty growth; failure of the slower progression
or reduction of diabetic retinopathy resulting from the Retisert™ implant to
have significant implications for Retisert™ and Medidur; failure of our
evaluation agreements to result in license agreements; failure of Medidur™ to
release the same drug as Retisert™ at the same rate; failure of the
Medidur™
trials
in DME to show a very similar stabilization or improvement diabetic retinopathy
as Retisert™
for DME.
Other
reasons are contained in cautionary statements in the Registration Statement
on
Form 20-F filed with the U.S. Securities and Exchange Commission, including,
without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake
to update any oral or written forward-looking statements that may be made by
or
on behalf of pSivida.